Cosciens Biopharma — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Cosciens Biopharma operates a dual business model combining a commercial natural ingredients division with a pharmaceutical development arm. The company's core technology involves proprietary extraction and manufacturing processes for bioactive compounds from oats, which are sold as active ingredients to major consumer brands and developed for therapeutic uses. Its lead commercial pharmaceutical asset is Macimorelin, an approved oral diagnostic for growth hormone deficiency. Founded in 2020 and led by an interim CEO with a financial background, Cosciens aims to bridge natural product science with clinical applications across dermatology, metabolic health, and diagnostics.

EndocrinologyDermatologyMetabolic DisordersGastrointestinal

Technology Platform

Proprietary manufacturing and extraction technologies for isolating and purifying bioactive compounds from oats (Avena sativa), including Beta Glucan, Avenanthramides, and Oat Oil, for use in cosmeceutical, nutraceutical, and pharmaceutical applications.

Opportunities

The growing consumer and clinical demand for scientifically-validated natural ingredients in skincare and wellness provides a large, established market for its oat-derived actives.

The commercial diagnostic Macimorelin addresses an unmet need for a convenient, oral test in endocrinology, offering a pathway to capture market share in a specialized medical niche.

The underlying biology of its compounds suggests potential for expansion into large therapeutic areas like metabolic and inflammatory diseases.

Risk Factors

The company's revenue relies on commercial execution in two very different markets: competitive B2B ingredient sales and niche pharmaceutical diagnostics.

Leadership is interim and heavily finance-focused, which may indicate strategic uncertainty or a lack of dedicated biopharma operational expertise.

Advancing natural ingredients into approved pharmaceuticals requires significant capital and faces high regulatory and clinical development risks.

Competitive Landscape

In the natural active ingredients space, Cosciens competes with other botanical extract suppliers and large chemical companies offering functional actives. For Macimorelin, competition comes from traditional, invasive diagnostic methods for AGHD (e.g., insulin tolerance test) and possibly other diagnostic approaches. Its differentiation lies in its proprietary oat extraction technology and the unique dual commercial/pharma business model.

More companies in Biologics / Biosimilars →More companies in United States →